| Literature DB >> 20457821 |
Yen-Liang Chen1, Zheng Yin, Jeyaraj Duraiswamy, Wouter Schul, Chin Chin Lim, Boping Liu, Hao Ying Xu, Min Qing, Andy Yip, Gang Wang, Wai Ling Chan, Hui Pen Tan, Melissa Lo, Sarah Liung, Ravinder Reddy Kondreddi, Ranga Rao, Helen Gu, Handan He, Thomas H Keller, Pei-Yong Shi.
Abstract
We recently reported that (2R,3R,4R,5R)-2-(4-amino-pyrrolo[2,3-d]pyrimidin-7-yl)-3-ethynyl-5-hydroxy-methyl-tetrahydro-furan-3,4-diol is a potent inhibitor of dengue virus (DENV), with 50% effective concentration (EC(50)) and cytotoxic concentration (CC(50)) values of 0.7 microM and >100 microM, respectively. Here we describe the synthesis, structure-activity relationship, and antiviral characterization of the inhibitor. In an AG129 mouse model, a single-dose treatment of DENV-infected mice with the compound suppressed peak viremia and completely prevented death. Mode-of-action analysis using a DENV replicon indicated that the compound blocks viral RNA synthesis. Recombinant adenosine kinase could convert the compound to a monophosphate form. Suppression of host adenosine kinase, using a specific inhibitor (iodotubercidin) or small interfering RNA (siRNA), abolished or reduced the compound's antiviral activity in cell culture. Studies of rats showed that (14)C-labeled compound was converted to mono-, di-, and triphosphate metabolites in vivo. Collectively, the results suggest that this adenosine inhibitor is phosphorylated to an active (triphosphate) form which functions as a chain terminator for viral RNA synthesis.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20457821 PMCID: PMC2897296 DOI: 10.1128/AAC.00140-10
Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN: 0066-4804 Impact factor: 5.191